Items tagged with Medicines
Sanofi launches new Priftin® (rifapentine) packaging (post with simple image)
BRIDGEWATER, N.J., Dec. 1, 2015 -- Sanofi announced today the launch of a new 24-count tablet pack of Priftin® (rifapentine) for the treatment of latent tuberculosis infection (LTBI) in patients two years of age and older who are at high risk of progression to tuberculosis (TB) disease. The new 24-count package is tailored for use in the treatment of LTBI and represents one month of Priftin for most patients. The new 24-count packaging features individual tablet printing on the backing foil with individually perforated tablet blisters, and has an extended shelf-life of up to three years.
Phase 1 clinical trial of TB drug candidate TBA-354 discontinued (post with simple image)
More investment is needed to expand the portfolio of new TB drug candidates.
Advocates commend Johns Hopkins University for pursuing a public health driven path for sutezolid’s development (post with simple image)
TB advocates congratulate Johns Hopkins University’s decision to enter negotiations with the Medicines Patent Pool regarding the licensing of worldwide non-exclusive rights to sutezolid.
2016 i-Base/TAG Pipeline Report (post with simple image)
Latest annual review on HIV and TB drugs, diagnostics, vaccines, preventive technologies, research toward a cure, and immune-based and gene therapies in development.
Advocates call on pharma companies to improve access to MDR-TB drugs (post with simple image)
TB advocates urge Janssen and Otsuka to improve the affordability and availability of bedaquiline and delamanid.
An Activist’s Guide to Tuberculosis Drugs 2016 Update (post with simple image)
The guide provides a brief summary of safety and efficacy data for the drugs currently in use for TB, and suggests advocacy points for activists.
WHO launches a global database for aDSM (post with simple image)
The Global TB Programme and the Special Programme for Research and Training in Tropical Diseases at the World Health Organization launch a global database for active TB drug safety monitoring and management (aDSM). Countries are now invited to contribute data to the global database.
MSF calls on Johnson & Johnson to improve access to bedaquiline (post with simple image)
Médecins Sans Frontières (MSF) urges Johnson & Johnson to ensure widespread access to bedaquiline for the treatment of multidrug-resistant TB.
Public health groups welcome Johns Hopkins University and Medicines Patent Pool agreement for development of promising new TB drug (post with simple image)
While deal marks a critical step in the fight against TB, health groups warn that the deal lacks safeguards that would ensure worldwide affordability.
Advocates call on Sequella to provide open access to sutezolid data (post with simple image)
TB advocates appeal to Sequella to act in the interest of public health and provide open access to all existing sutezolid data.
Page 9 of 10 · Total posts: 0←First 8 9 10 Last→